SE464300B - Beta-adrenergiskt blockerande foerening samt kompositioner foer behandling av glaukom - Google Patents
Beta-adrenergiskt blockerande foerening samt kompositioner foer behandling av glaukomInfo
- Publication number
- SE464300B SE464300B SE8300912A SE8300912A SE464300B SE 464300 B SE464300 B SE 464300B SE 8300912 A SE8300912 A SE 8300912A SE 8300912 A SE8300912 A SE 8300912A SE 464300 B SE464300 B SE 464300B
- Authority
- SE
- Sweden
- Prior art keywords
- carbon atoms
- hydroxy
- butyl
- compound
- composition according
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 10
- 239000000203 mixture Substances 0.000 title claims description 35
- 230000000903 blocking effect Effects 0.000 title claims description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 87
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 31
- 230000004410 intraocular pressure Effects 0.000 claims abstract description 18
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 125000000304 alkynyl group Chemical group 0.000 claims abstract description 9
- 208000010412 Glaucoma Diseases 0.000 claims abstract description 8
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims abstract description 7
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 4
- 125000003118 aryl group Chemical group 0.000 claims abstract description 4
- -1 nitro, amino Chemical group 0.000 claims description 60
- 125000004432 carbon atom Chemical group C* 0.000 claims description 57
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 23
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 17
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 17
- 239000000460 chlorine Substances 0.000 claims description 14
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 150000002367 halogens Chemical group 0.000 claims description 13
- 125000002252 acyl group Chemical group 0.000 claims description 12
- 125000004423 acyloxy group Chemical group 0.000 claims description 12
- 125000001589 carboacyl group Chemical group 0.000 claims description 12
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 9
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 9
- 229910052801 chlorine Inorganic materials 0.000 claims description 9
- 239000011737 fluorine Substances 0.000 claims description 9
- 229910052731 fluorine Inorganic materials 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 claims description 4
- 239000000644 isotonic solution Substances 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 4
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims description 3
- 101150065749 Churc1 gene Proteins 0.000 claims description 3
- 102100038239 Protein Churchill Human genes 0.000 claims description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 3
- 230000002335 preservative effect Effects 0.000 claims description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 2
- 229960002216 methylparaben Drugs 0.000 claims description 2
- DCNLOVYDMCVNRZ-UHFFFAOYSA-N phenylmercury(.) Chemical class [Hg]C1=CC=CC=C1 DCNLOVYDMCVNRZ-UHFFFAOYSA-N 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 229960003415 propylparaben Drugs 0.000 claims description 2
- 150000003856 quaternary ammonium compounds Chemical class 0.000 claims description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims description 2
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims 3
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 235000019445 benzyl alcohol Nutrition 0.000 claims 1
- 229960004217 benzyl alcohol Drugs 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 13
- 230000001839 systemic circulation Effects 0.000 abstract description 6
- 239000012530 fluid Substances 0.000 abstract description 5
- 241000124008 Mammalia Species 0.000 abstract description 3
- 230000009885 systemic effect Effects 0.000 abstract description 3
- 150000002148 esters Chemical class 0.000 abstract description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 13
- 235000002639 sodium chloride Nutrition 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 11
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 11
- 238000002329 infrared spectrum Methods 0.000 description 10
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 239000002876 beta blocker Substances 0.000 description 8
- 229940097320 beta blocking agent Drugs 0.000 description 8
- 238000000921 elemental analysis Methods 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 210000001742 aqueous humor Anatomy 0.000 description 7
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 7
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 5
- 240000005578 Rivina humilis Species 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 230000007071 enzymatic hydrolysis Effects 0.000 description 5
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- ONIKNECPXCLUHT-UHFFFAOYSA-N 2-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1Cl ONIKNECPXCLUHT-UHFFFAOYSA-N 0.000 description 4
- 108090000371 Esterases Proteins 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- KBPUBCVJHFXPOC-UHFFFAOYSA-N ethyl 3,4-dihydroxybenzoate Chemical compound CCOC(=O)C1=CC=C(O)C(O)=C1 KBPUBCVJHFXPOC-UHFFFAOYSA-N 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CTKINSOISVBQLD-UHFFFAOYSA-N Glycidol Chemical compound OCC1CO1 CTKINSOISVBQLD-UHFFFAOYSA-N 0.000 description 3
- 238000004566 IR spectroscopy Methods 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 3
- 150000002924 oxiranes Chemical class 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- RAAGZOYMEQDCTD-UHFFFAOYSA-N 2-fluorobenzoyl chloride Chemical compound FC1=CC=CC=C1C(Cl)=O RAAGZOYMEQDCTD-UHFFFAOYSA-N 0.000 description 2
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 2
- JWBMVCAZXJMSOX-UHFFFAOYSA-N 3-(tert-butylamino)propane-1,2-diol Chemical compound CC(C)(C)NCC(O)CO JWBMVCAZXJMSOX-UHFFFAOYSA-N 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DIWOLIKOVWAKME-UHFFFAOYSA-N [3-(tert-butylamino)-2-hydroxypropyl] 3,4-bis(phenylmethoxy)benzoate Chemical compound C=1C=CC=CC=1COC1=CC(C(=O)OCC(O)CNC(C)(C)C)=CC=C1OCC1=CC=CC=C1 DIWOLIKOVWAKME-UHFFFAOYSA-N 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- LBAQSKZHMLAFHH-UHFFFAOYSA-N ethoxyethane;hydron;chloride Chemical compound Cl.CCOCC LBAQSKZHMLAFHH-UHFFFAOYSA-N 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229940050410 gluconate Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 2
- NQBRFIXRZDTIRQ-UHFFFAOYSA-N (4-methoxyphenyl)methyl n-diazocarbamate Chemical compound COC1=CC=C(COC(=O)N=[N+]=[N-])C=C1 NQBRFIXRZDTIRQ-UHFFFAOYSA-N 0.000 description 1
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
- JMDWXHFNOBYBDC-UHFFFAOYSA-N 1-amino-5-(3,4-dimethoxyphenyl)pentane-1,2-diol Chemical compound COC=1C=C(C=CC1OC)CCCC(C(O)N)O JMDWXHFNOBYBDC-UHFFFAOYSA-N 0.000 description 1
- GYEYPHBTKAEWHH-UHFFFAOYSA-N 2,3-bis(phenylmethoxy)benzoic acid Chemical compound C=1C=CC=CC=1COC=1C(C(=O)O)=CC=CC=1OCC1=CC=CC=C1 GYEYPHBTKAEWHH-UHFFFAOYSA-N 0.000 description 1
- VUGCBIWQHSRQBZ-UHFFFAOYSA-N 2-methylbut-3-yn-2-amine Chemical compound CC(C)(N)C#C VUGCBIWQHSRQBZ-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- GMOYUTKNPLBTMT-UHFFFAOYSA-N 2-phenylmethoxybenzoic acid Chemical class OC(=O)C1=CC=CC=C1OCC1=CC=CC=C1 GMOYUTKNPLBTMT-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- BYOKJLCIKSFPDU-UHFFFAOYSA-N 3,4-bis(phenylmethoxy)benzoic acid Chemical compound C=1C=CC=CC=1COC1=CC(C(=O)O)=CC=C1OCC1=CC=CC=C1 BYOKJLCIKSFPDU-UHFFFAOYSA-N 0.000 description 1
- CZKLEJHVLCMVQR-UHFFFAOYSA-N 4-fluorobenzoyl chloride Chemical compound FC1=CC=C(C(Cl)=O)C=C1 CZKLEJHVLCMVQR-UHFFFAOYSA-N 0.000 description 1
- FYDIVWLLJXNXCE-UHFFFAOYSA-N 4-formylbenzoyl chloride Chemical compound ClC(=O)C1=CC=C(C=O)C=C1 FYDIVWLLJXNXCE-UHFFFAOYSA-N 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- AQSCHALQLXXKKC-UHFFFAOYSA-N 4-phenylmethoxybenzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1OCC1=CC=CC=C1 AQSCHALQLXXKKC-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BPLVZVIMRZHNQC-UHFFFAOYSA-N C(CC)OC(C1C2(C(=CC=C1)O2)Cl)=O Chemical compound C(CC)OC(C1C2(C(=CC=C1)O2)Cl)=O BPLVZVIMRZHNQC-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241000556720 Manga Species 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical class [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000007073 chemical hydrolysis Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000003055 glycidyl group Chemical group C(C1CO1)* 0.000 description 1
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940039748 oxalate Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- YOLFMTDVRJWTQZ-UHFFFAOYSA-N oxiran-2-ylmethyl 2-fluorobenzoate Chemical compound FC1=CC=CC=C1C(=O)OCC1OC1 YOLFMTDVRJWTQZ-UHFFFAOYSA-N 0.000 description 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- MDDFICUIFWUSDO-UHFFFAOYSA-N propyl 4-(hydroxymethyl)benzoate Chemical compound CCCOC(=O)C1=CC=C(CO)C=C1 MDDFICUIFWUSDO-UHFFFAOYSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 235000011091 sodium acetates Nutrition 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- KEAYESYHFKHZAL-OUBTZVSYSA-N sodium-24 Chemical compound [24Na] KEAYESYHFKHZAL-OUBTZVSYSA-N 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C219/14—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to a carbon atom of a six-membered aromatic ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/276,657 US4402974A (en) | 1981-06-23 | 1981-06-23 | Method for treating glaucoma by the topical administration of selectively metabolized beta-blocking agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE8300912D0 SE8300912D0 (sv) | 1983-02-18 |
| SE8300912L SE8300912L (sv) | 1983-02-18 |
| SE464300B true SE464300B (sv) | 1991-04-08 |
Family
ID=23057572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8300912A SE464300B (sv) | 1981-06-23 | 1983-02-18 | Beta-adrenergiskt blockerande foerening samt kompositioner foer behandling av glaukom |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US4402974A (de) |
| EP (1) | EP0081580B1 (de) |
| JP (1) | JPS58500997A (de) |
| AT (1) | AT384017B (de) |
| AU (1) | AU559541B2 (de) |
| CA (1) | CA1272733C (de) |
| CH (1) | CH655497B (de) |
| ES (1) | ES8401927A1 (de) |
| GB (2) | GB2112785B (de) |
| GR (1) | GR76848B (de) |
| IL (1) | IL66069A0 (de) |
| IT (1) | IT1156057B (de) |
| NL (1) | NL8220251A (de) |
| NZ (1) | NZ200971A (de) |
| PH (1) | PH18383A (de) |
| SE (1) | SE464300B (de) |
| WO (1) | WO1983000043A1 (de) |
| ZA (1) | ZA824339B (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1582884A (en) * | 1977-05-19 | 1981-01-14 | Beecham Group Ltd | Clavulanic acid derivatives their preparation and use |
| DK330880A (da) * | 1979-08-03 | 1981-02-04 | Beecham Group Ltd | Fremgangsmaade til fremstilling af clavulansyrederivater |
| US4604481A (en) * | 1980-11-28 | 1986-08-05 | American Hospital Supply Corporation | Compounds for treatment or prophylaxis of cardiac disorders |
| DE3169452D1 (en) * | 1980-12-09 | 1985-04-25 | Beecham Group Plc | Derivatives of clavulanic acid, their preparation and their use |
| US4562182A (en) * | 1980-12-23 | 1985-12-31 | Beecham Group P.L.C. | Compounds containing beta-lactams |
| US4579867A (en) * | 1984-04-09 | 1986-04-01 | American Hospital Supply Corporation | Stable pharmaceutical compositions of short-acting β-adrenergic receptor blocking agents |
| CA1334168C (en) * | 1988-04-26 | 1995-01-31 | Louis M. De Santis | Antiglaucoma compositions containing combinations of .alpha.-2 agonists and .beta. blockers |
| US4897417A (en) * | 1988-12-15 | 1990-01-30 | E. I. Du Pont De Nemours & Co. | Prodrugs of 3,4-hydroxy benzoyloxypropanolamines |
| US4966914A (en) * | 1988-12-15 | 1990-10-30 | E. I. Du Pont De Nemours And Company | Oculoselective beta-blockers as antiglaucoma agents |
| CH679856A5 (de) * | 1990-07-04 | 1992-04-30 | Lonza Ag | |
| US5629345A (en) * | 1993-07-23 | 1997-05-13 | Vide Pharmaceuticals | Methods and compositions for ATP-sensitive K+ channel inhibition for lowering intraocular pressure |
| US5965620A (en) * | 1993-07-23 | 1999-10-12 | Vide Pharmaceuticals | Methods and compositions for ATP-sensitive K+ channel inhibition for lowering intraocular pressure |
| US5543083A (en) * | 1994-07-26 | 1996-08-06 | The Procter & Gamble Company | Fatty amine derivatives of butylated hydroxy toluene for the protection of surfaces from physical and chemical degradation |
| US5536749A (en) * | 1994-10-13 | 1996-07-16 | Sl Pharmaceuticals, Inc. | Method for attenuation of sympathetic nervous system activity or onset of migraine by selectively metabolized beta-blocking agents |
| US6197817B1 (en) | 1999-01-22 | 2001-03-06 | Selectus Pharmaceuticals, Inc. | Phenylpropionic acids and esters: compounds and methods for inducing beta-blockade for the treatment of cardiac disorders |
| US7209743B2 (en) * | 2004-04-22 | 2007-04-24 | Telefonaktiebolaget Lm Ericsson (Publ) | Base station system and method for compensating traffic channel signal strength measurements in a cellular radio telecommunication network |
| ZA200610032B (en) * | 2004-05-25 | 2008-11-26 | Othera Holding Inc | Oculoselective drugs and prodrugs |
| CA2576279A1 (en) * | 2004-11-08 | 2006-05-18 | Nitromed, Inc. | Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL75127C (de) * | 1943-10-05 | |||
| FR1047364A (fr) * | 1950-12-28 | 1953-12-14 | Hoechst Ag | Esters d'acides alcoylamino-benzoïques, sels d'acides minéraux de ces esters et procédé de préparation de ces corps |
| NL300886A (de) * | 1962-11-23 | |||
| US3959351A (en) * | 1972-07-24 | 1976-05-25 | Research Corporation | Haloalkylbenzoyl esters of di-lower alkylamino alkanols and quaternary lower alkyl salts thereof |
| US4195085A (en) * | 1975-09-26 | 1980-03-25 | Merck & Co., Inc. | Compositions and methods for treating glaucoma by the topical administration of t-butylamino-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy-2-phopanol hydrogen maleate |
| DE2752659A1 (de) | 1976-12-07 | 1978-06-08 | Sandoz Ag | Neue tetralinderivate, ihre herstellung und verwendung |
| US4127674A (en) * | 1977-03-21 | 1978-11-28 | Allergan Pharmaceuticals, Inc. | Method of treatment for glaucoma |
| DE2962112D1 (en) * | 1978-02-08 | 1982-03-25 | Ici Plc | Alkanolamine derivatives, process for their preparation and pharmaceutical compositions containing them |
| US4405642A (en) * | 1980-11-28 | 1983-09-20 | American Hospital Supply Corporation | Method for treatment or prophylaxis of cardiac disorders |
-
1981
- 1981-06-23 US US06/276,657 patent/US4402974A/en not_active Expired - Fee Related
-
1982
- 1982-06-14 CA CA 405106 patent/CA1272733C/xx not_active Expired - Lifetime
- 1982-06-14 PH PH27417A patent/PH18383A/en unknown
- 1982-06-15 NZ NZ200971A patent/NZ200971A/en unknown
- 1982-06-16 IL IL66069A patent/IL66069A0/xx not_active IP Right Cessation
- 1982-06-18 ZA ZA824339A patent/ZA824339B/xx unknown
- 1982-06-18 GR GR68484A patent/GR76848B/el unknown
- 1982-06-22 IT IT67795/82A patent/IT1156057B/it active
- 1982-06-23 NL NL8220251A patent/NL8220251A/nl unknown
- 1982-06-23 AT AT0903482A patent/AT384017B/de not_active IP Right Cessation
- 1982-06-23 ES ES513386A patent/ES8401927A1/es not_active Expired
- 1982-06-23 GB GB08303060A patent/GB2112785B/en not_active Expired
- 1982-06-23 JP JP57502294A patent/JPS58500997A/ja active Granted
- 1982-06-23 WO PCT/US1982/000848 patent/WO1983000043A1/en active IP Right Grant
- 1982-06-23 CH CH110483A patent/CH655497B/de unknown
- 1982-06-23 EP EP82902332A patent/EP0081580B1/de not_active Expired
- 1982-06-23 AU AU87375/82A patent/AU559541B2/en not_active Ceased
-
1983
- 1983-02-18 SE SE8300912A patent/SE464300B/sv not_active IP Right Cessation
-
1984
- 1984-08-30 GB GB08421939A patent/GB2145721B/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| SE8300912D0 (sv) | 1983-02-18 |
| GB8421939D0 (en) | 1984-10-03 |
| US4402974A (en) | 1983-09-06 |
| ES513386A0 (es) | 1984-01-01 |
| NL8220251A (nl) | 1983-05-02 |
| NZ200971A (en) | 1985-12-13 |
| WO1983000043A1 (en) | 1983-01-06 |
| ATA903482A (de) | 1987-02-15 |
| GB8303060D0 (en) | 1983-03-09 |
| IT1156057B (it) | 1987-01-28 |
| AU559541B2 (en) | 1987-03-12 |
| GB2145721A (en) | 1985-04-03 |
| AT384017B (de) | 1987-09-25 |
| EP0081580A4 (de) | 1983-12-01 |
| ES8401927A1 (es) | 1984-01-01 |
| IT8267795A0 (it) | 1982-06-22 |
| ZA824339B (en) | 1983-04-27 |
| GB2112785B (en) | 1985-06-05 |
| AU8737582A (en) | 1983-01-18 |
| GB2145721B (en) | 1986-02-19 |
| CH655497B (de) | 1986-04-30 |
| GR76848B (de) | 1984-09-04 |
| IL66069A0 (en) | 1982-09-30 |
| CA1272733C (en) | 1990-08-14 |
| GB2112785A (en) | 1983-07-27 |
| SE8300912L (sv) | 1983-02-18 |
| JPH0428696B2 (de) | 1992-05-15 |
| PH18383A (en) | 1985-06-19 |
| JPS58500997A (ja) | 1983-06-23 |
| EP0081580B1 (de) | 1987-04-22 |
| CA1220716A (en) | 1987-04-21 |
| EP0081580A1 (de) | 1983-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE464300B (sv) | Beta-adrenergiskt blockerande foerening samt kompositioner foer behandling av glaukom | |
| EP0682664B1 (de) | Verbindungen die sowohl starke calcium-antagonistische und antioxydatieve aktivitaet haben und deren verwendung als zellschuetzende mittel. | |
| EP0617960B1 (de) | Verwendung von Pyridoxal-Derivaten zur Herstellung eines Arzneimittels zur Behandlung des Katarakts | |
| US5677335A (en) | 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic acid anilides for the treatment of ocular disease | |
| EP0413329B1 (de) | 5-Methylisoxazol-4-carbonsäure-anilide und 2-Hydroxyethyliden-cyanoessigsäure-anilide zur Behandlung von Augenkrankheiten | |
| RU2218334C2 (ru) | Замещенные 1,2,3,4,5,6-гексагидро-2,6-метано-3-бензазоцин-10-олы и фармацевтическая композиция на их основе | |
| SE462075B (sv) | Oftalmologisk komposition foer behandling av glukom innehaallande kortverkande b-blockerande foereningar | |
| US4070464A (en) | Method of treating autoimmune diseases | |
| BR112019009330A2 (pt) | composto | |
| AU558475B2 (en) | Compositions for treating glaucoma | |
| US4855415A (en) | Glucosylmoranoline derivatives | |
| EP0373592B1 (de) | Oculoselektive beta-Blocker als Antiglaukommittel | |
| US5585377A (en) | Sulfonamides useful as carbonic anhydrase inhibitors | |
| US4501912A (en) | Method for treating glaucoma by the topical administration of selectively metabolized beta-blocking agents | |
| US4556668A (en) | Ethylenediamine derivatives of aryloxypropanolamine aryl esters having various medicinal properties | |
| JPH03141284A (ja) | ４―（２―メチル―２―ヒドロキシプロピルアミノ）―５，６―ジヒドロチエノ―〔２，３―ｂ〕チオピラン―２―スルホンアミド―７，７―ジオキシド | |
| US5464831A (en) | Thienothiadiazine sulfonamides useful as carbonic anhydrase inhibitors | |
| CA1272733A (en) | Compositions for treating glaucoma | |
| US4119643A (en) | 4-Amino-6-nitro derivatives of 2H-3,4-dihydrobenzo[b]pyrans | |
| US2426276A (en) | Preparations active against cocci infections | |
| US4505923A (en) | Ethers of hydroxybenzothiazole-2-sulfonamide for the topical treatment of elevated intraocular pressure | |
| RU95107147A (ru) | Производные циклогексанкарбоновой кислоты, смесь их изомеров или отдельные изомеры и физиологически переносимые соли и фармацевтическая композиция с тормозящей ферментный комплекс глюкоза-6-фосфатазы печени активностью | |
| US4929549A (en) | 5-carbamoylthieno[2,3-b]thiophene-2-sulfon-amides as topically active carbonic anhydrase inhibitors | |
| US4677105A (en) | 2-alkoxycarbonylalkyl-3-oxo-5,6-diaryl-as-triazines having utility as therapeutics | |
| AU682319B2 (en) | Ethynyl alanine amino diol compounds having a piperazinyl-terminated group or piperazinyl-alkylamino-terminated group for treatment of hypertension |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |
Ref document number: 8300912-6 Effective date: 19940110 Format of ref document f/p: F |